Cell Signaling Technology Logo - Extra Large
Trial Size Available Flag
Recombinant Flag
Recombinant: Superior lot-to-lot consistency, continuous supply, and animal-free manufacturing.

ACSL5 (F8M1Q) Rabbit Monoclonal Antibody #64758

Filter:
  • WB
  • IP
  • IF

    Product Specifications

    REACTIVITY H
    SENSITIVITY Endogenous
    MW (kDa) 65, 70
    Source/Isotype Rabbit IgG
    Application Key:
    • WB-Western Blotting 
    • IP-Immunoprecipitation 
    • IF-Immunofluorescence 
    Species Cross-Reactivity Key:
    • H-Human 

    Product Information

    Product Usage Information

    Application Dilution
    Western Blotting 1:1000
    Immunoprecipitation 1:50
    Immunofluorescence (Immunocytochemistry) 1:1600

    Storage

    Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/mL BSA, 50% glycerol, and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.

    Protocol

    Specificity / Sensitivity

    ACSL5 (F8M1Q) Rabbit Monoclonal Antibody recognizes endogenous levels of total ACSL5 protein. This antibody does not cross-react with ACSL1, ACSL3, or ACSL4 protein.

    Species Reactivity:

    Human

    Source / Purification

    Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues near the carboxy terminus of human ACSL5 protein.

    Background

    Acyl-CoA synthetase long-chain family member 5 (ACSL5), also known as a long-chain acyl-CoA synthetase 5 (LACS 5), catalyzes the conversion of long-chain fatty acids to corresponding acyl-CoAs in a two-step reaction, activating long-chain fatty acids (1,2,4). Studies show that SIRT6 binds palmitic acid, leading to its translocation from the nucleus to the cytoplasm. SIRT6 then deacetylates ACSL5, stimulating fatty acid oxidation and inhibiting lipid accumulation. Furthermore, these findings suggest a role of cytoplasmic SIRT6/ACSL5 signaling in nonalcoholic fatty liver disease (NAFLD) progression (3). Additionally, ACSL5 has been shown to function as an immune-dependent tumor suppressor. ACSL5 sensitizes tumor cells to CD8+ T cell-mediated cytotoxicity in vitro and PD-1 blockade therapy in vivo.

    Alternate Names

    ACS2; ACS5; ACSL5; acyl-CoA synthetase long chain family member 5; acyl-CoA synthetase long-chain family member 5; Arachidonate--CoA ligase; FACL5; FACL5 for fatty acid coenzyme A ligase 5; fatty acid coenzyme A ligase 5; fatty-acid-Coenzyme A ligase, long-chain 5; LACS 5; Long-chain acyl-CoA synthetase 5; long-chain fatty acid coenzyme A ligase 5; Long-chain-fatty-acid--CoA ligase 5

    For Research Use Only. Not for Use in Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.